Last reviewed · How we verify
Complicated Streptococcus Peritonitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Maxipime | CEFEPIME | Baxter | Cephalosporin Antibacterial | 1996-01-01 | ||
| Maxipime | Cefepime Hydrochloride | Baxter | Cephalosporin | Bacterial cell wall peptidoglycan | 1996-01-01 | |
| Cefepim | Cefepim | University Hospital Tuebingen | Bacterial penicillin-binding protein |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 2 drugs in Complicated Streptococcus Peritonitis
- · 1 drug in Complicated Streptococcus Peritonitis
- University Hospital Tuebingen · 1 drug in Complicated Streptococcus Peritonitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Complicated Streptococcus Peritonitis:
- Complicated Streptococcus Peritonitis treatment updates — RSS
- Complicated Streptococcus Peritonitis treatment updates — Atom
- Complicated Streptococcus Peritonitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Complicated Streptococcus Peritonitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-streptococcus-peritonitis. Accessed 2026-06-10.
Related
- Complicated Streptococcus Peritonitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing